PortfoliosLab logo
CPRX vs. AADI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CPRX and AADI is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

CPRX vs. AADI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Aadi Bioscience, Inc. (AADI). The values are adjusted to include any dividend payments, if applicable.

0.00%20.00%40.00%60.00%80.00%NovemberDecember2025FebruaryMarchApril
15.52%
1.36%
CPRX
AADI

Key characteristics

Sharpe Ratio

CPRX:

1.22

AADI:

-0.09

Sortino Ratio

CPRX:

2.08

AADI:

0.44

Omega Ratio

CPRX:

1.23

AADI:

1.05

Calmar Ratio

CPRX:

1.62

AADI:

-0.07

Martin Ratio

CPRX:

7.34

AADI:

-0.28

Ulcer Index

CPRX:

6.67%

AADI:

24.86%

Daily Std Dev

CPRX:

40.17%

AADI:

77.36%

Max Drawdown

CPRX:

-94.25%

AADI:

-98.67%

Current Drawdown

CPRX:

-10.37%

AADI:

-97.96%

Fundamentals

Market Cap

CPRX:

$2.93B

AADI:

$94.89M

EPS

CPRX:

$1.31

AADI:

-$2.36

Total Revenue (TTM)

CPRX:

$393.23M

AADI:

$20.63M

Gross Profit (TTM)

CPRX:

$327.56M

AADI:

$18.26M

EBITDA (TTM)

CPRX:

$177.46M

AADI:

-$45.84M

Returns By Period

In the year-to-date period, CPRX achieves a 10.54% return, which is significantly higher than AADI's -35.97% return.


CPRX

YTD

10.54%

1M

5.39%

6M

15.35%

1Y

52.58%

5Y*

45.69%

10Y*

17.43%

AADI

YTD

-35.97%

1M

-8.60%

6M

4.12%

1Y

-6.91%

5Y*

-24.22%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CPRX vs. AADI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
The Risk-Adjusted Performance Rank of CPRX is 8989
Overall Rank
The Sharpe Ratio Rank of CPRX is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8888
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 8383
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 9292
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 9292
Martin Ratio Rank

AADI
The Risk-Adjusted Performance Rank of AADI is 5252
Overall Rank
The Sharpe Ratio Rank of AADI is 5151
Sharpe Ratio Rank
The Sortino Ratio Rank of AADI is 5555
Sortino Ratio Rank
The Omega Ratio Rank of AADI is 5454
Omega Ratio Rank
The Calmar Ratio Rank of AADI is 5151
Calmar Ratio Rank
The Martin Ratio Rank of AADI is 5151
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CPRX vs. AADI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Aadi Bioscience, Inc. (AADI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for CPRX, currently valued at 1.22, compared to the broader market-2.00-1.000.001.002.00
CPRX: 1.22
AADI: -0.10
The chart of Sortino ratio for CPRX, currently valued at 2.08, compared to the broader market-6.00-4.00-2.000.002.004.00
CPRX: 2.08
AADI: 0.41
The chart of Omega ratio for CPRX, currently valued at 1.23, compared to the broader market0.501.001.502.00
CPRX: 1.23
AADI: 1.05
The chart of Calmar ratio for CPRX, currently valued at 1.62, compared to the broader market0.001.002.003.004.00
CPRX: 1.62
AADI: -0.08
The chart of Martin ratio for CPRX, currently valued at 7.34, compared to the broader market-10.000.0010.0020.00
CPRX: 7.34
AADI: -0.33

The current CPRX Sharpe Ratio is 1.22, which is higher than the AADI Sharpe Ratio of -0.09. The chart below compares the historical Sharpe Ratios of CPRX and AADI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
1.22
-0.10
CPRX
AADI

Dividends

CPRX vs. AADI - Dividend Comparison

Neither CPRX nor AADI has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CPRX vs. AADI - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum AADI drawdown of -98.67%. Use the drawdown chart below to compare losses from any high point for CPRX and AADI. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-10.37%
-97.96%
CPRX
AADI

Volatility

CPRX vs. AADI - Volatility Comparison

Catalyst Pharmaceuticals, Inc. (CPRX) and Aadi Bioscience, Inc. (AADI) have volatilities of 13.15% and 12.57%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
13.15%
12.57%
CPRX
AADI

Financials

CPRX vs. AADI - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Aadi Bioscience, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items